Business · 29/10/2004Updated: 10/17/2026 · 1 min read

National Institutes of Health to Consider Exclusive License for Dengue Vaccine

Summary

The National Institutes of Health is issuing a notice of its intention to grant an exclusive license for a dengue vaccine that contains a specific 30-nucleotide deletion in the 3'-UTR of dengue types 1, 2, 3, and 4, as outlined in several patent applications.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 9/16/2026

NIH Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form

The National Institutes of Health (NIH) is proposing a web-based reporting form to help the Agency Intramural Research Integrity Officer (AIRIO) assess concerns and determine appropriate next steps in evaluating allegations of research misconduct.

Read summary →

Business · 9/14/2026

NIH Proposes Enhanced Biosafety Policy for Biohazard Research

The National Institutes of Health is seeking public input on a new, comprehensive biosafety policy aimed at strengthening oversight and keeping pace with evolving biohazard risks, with the goal of ensuring gold-standard science under gold-standard biosafety conditions.

Read summary →

Business · 9/14/2026

NIH Requests Public Comment on Proposed Collection of Data for NIH Certificates of Confidentiality

The National Institutes of Health (NIH) is seeking public comment on a proposed data collection project, as required by the Paperwork Reduction Act of 1995, before submitting it to the Office of Management and Budget (OMB) for review and approval.

Read summary →

Business · 9/14/2026

Office of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; Amended Notice of Meeting

The Office of the National Coordinator for Health Information Technology and the Health Information Technology Advisory Committee have issued an amended notice regarding a meeting, which appears to be a formal announcement of a scheduled event.

Read summary →

Business · 9/16/2026

Government-Owned Inventions; Availability for Licensing

The National Institute of Allergy and Infectious Diseases (NIAID) is giving notice of a government-owned invention available for licensing to achieve commercialization of federally funded research results.

Read summary →